Essential hypertension has a heritability as high as 30 -50%, but its genetic cause(s) has not been determined despite intensive investigation. The renal dopaminergic system exerts a pivotal role in maintaining fluid and electrolyte balance and participates in the pathogenesis of genetic hypertension. In genetic hypertension, the ability of dopamine and D1-like agonists to increase urinary sodium excretion is impaired. A defective coupling between the D1 dopamine receptor and the G protein͞effector enzyme complex in the proximal tubule of the kidney is the cause of the impaired renal dopaminergic action in genetic rodent and human essential hypertension. We now report that, in human essential hypertension, single nucleotide polymorphisms of a G protein-coupled receptor kinase, GRK4␥, increase G protein-coupled receptor kinase (GRK) activity and cause the serine phosphorylation and uncoupling of the D1 receptor from its G protein͞effector enzyme complex in the renal proximal tubule and in transfected Chinese hamster ovary cells. Moreover, expressing GRK4␥A142V but not the wild-type gene in transgenic mice produces hypertension and impairs the diuretic and natriuretic but not the hypotensive effects of D1-like agonist stimulation. These findings provide a mechanism for the D1 receptor coupling defect in the kidney and may explain the inability of the kidney to properly excrete sodium in genetic hypertension. L ong-term regulation of blood pressure is vested in the organ responsible for the control of body fluid volume, the kidney (1, 2). Dopamine facilitates the antihypertensive function of the kidney because it is both vasodilatory and natriuretic (3). Dopamine (produced by renal proximal tubules) via D 1 -like receptors is responsible for over 50% of incremental sodium excretion when sodium intake is increased (3-6). The paracrine͞ autocrine dopaminergic regulation of sodium excretion is mediated by tubular but not by hemodynamic mechanisms (6). The ability of dopamine and D 1 -like agonists to decrease renal proximal tubular sodium reabsorption is impaired in genetic rodent hypertension and human essential hypertension (3, 5, (7) (8) (9) (10) (11) (12) (13) (14) (15) . Indeed, the aberrant D 1 -like receptor function in the kidney precedes and cosegregates with high blood pressure in spontaneously hypertensive rats. In addition, disruption of the D 1 receptor in mice produces hypertension (12, 13). The pivotal role of dopamine in the excretion of sodium after increased sodium intake has led to the hypothesis that an aberrant renal dopaminergic system is important in the pathogenesis of some forms of genetic hypertension (3, 5, (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) . Several mechanisms potentially responsible for the failure of endogenous renal dopamine to engender a natriuretic effect in genetic hypertension have been investigated and ruled out, including decreased renal dopamine production and receptor expression, aberrant nephron segment distribution of dopamine receptors, defective effector enzymes (adenylyl cyclase or phospholipase C), and abnormal renal sodium transporters (3, 8, 13, 17) . Also, the coding region of the D 1 receptor is unchanged in hypertensive subjects (16), as well as in rodents with genetic hypertension (unpublished studies).
Essential hypertension has a heritability as high as 30 -50%, but its genetic cause(s) has not been determined despite intensive investigation. The renal dopaminergic system exerts a pivotal role in maintaining fluid and electrolyte balance and participates in the pathogenesis of genetic hypertension. In genetic hypertension, the ability of dopamine and D1-like agonists to increase urinary sodium excretion is impaired. A defective coupling between the D1 dopamine receptor and the G protein͞effector enzyme complex in the proximal tubule of the kidney is the cause of the impaired renal dopaminergic action in genetic rodent and human essential hypertension. We now report that, in human essential hypertension, single nucleotide polymorphisms of a G protein-coupled receptor kinase, GRK4␥, increase G protein-coupled receptor kinase (GRK) activity and cause the serine phosphorylation and uncoupling of the D1 receptor from its G protein͞effector enzyme complex in the renal proximal tubule and in transfected Chinese hamster ovary cells. Moreover, expressing GRK4␥A142V but not the wild-type gene in transgenic mice produces hypertension and impairs the diuretic and natriuretic but not the hypotensive effects of D1-like agonist stimulation. These findings provide a mechanism for the D1 receptor coupling defect in the kidney and may explain the inability of the kidney to properly excrete sodium in genetic hypertension. L ong-term regulation of blood pressure is vested in the organ responsible for the control of body fluid volume, the kidney (1, 2) . Dopamine facilitates the antihypertensive function of the kidney because it is both vasodilatory and natriuretic (3) . Dopamine (produced by renal proximal tubules) via D 1 -like receptors is responsible for over 50% of incremental sodium excretion when sodium intake is increased (3) (4) (5) (6) . The paracrine͞ autocrine dopaminergic regulation of sodium excretion is mediated by tubular but not by hemodynamic mechanisms (6) . The ability of dopamine and D 1 -like agonists to decrease renal proximal tubular sodium reabsorption is impaired in genetic rodent hypertension and human essential hypertension (3, 5, (7) (8) (9) (10) (11) (12) (13) (14) (15) . Indeed, the aberrant D 1 -like receptor function in the kidney precedes and cosegregates with high blood pressure in spontaneously hypertensive rats. In addition, disruption of the D 1 receptor in mice produces hypertension (12, 13) . The pivotal role of dopamine in the excretion of sodium after increased sodium intake has led to the hypothesis that an aberrant renal dopaminergic system is important in the pathogenesis of some forms of genetic hypertension (3, 5, (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) . Several mechanisms potentially responsible for the failure of endogenous renal dopamine to engender a natriuretic effect in genetic hypertension have been investigated and ruled out, including decreased renal dopamine production and receptor expression, aberrant nephron segment distribution of dopamine receptors, defective effector enzymes (adenylyl cyclase or phospholipase C), and abnormal renal sodium transporters (3, 8, 13, 17) . Also, the coding region of the D 1 receptor is unchanged in hypertensive subjects (16) , as well as in rodents with genetic hypertension (unpublished studies).
In renal proximal tubules from humans with essential hypertension and from rodents with genetic hypertension, the D 1 -like receptor is uncoupled from its G protein͞effector enzyme complex (3, (7) (8) (9) (10) 16 ). This uncoupling is thought to be the mechanism for the failure of dopamine to engender a natriuresis in genetic hypertension (3, 5, (11) (12) (13) (14) (15) . This mechanism is similar to but distinct from homologous desensitization (18, 19) because the uncoupling in hypertension is independent of renal dopamine levels (3, 16, 20) . Similarly, the uncoupling is not due to heterologous desensitization because the responsiveness of other G protein-coupled receptors (e.g., parathyroid hormone, ␤-adrenergic, and cholecystokinin receptors) remains intact in the prehypertensive spontaneously hypertensive rat (3, 8, (21) (22) (23) .
G protein-coupled receptor kinases (GRKs) have been implicated in genetic and acquired hypertension because they participate in the desensitization of G protein-coupled receptors, including D 1 receptors. The GRK-mediated desensitization is caused, in part, by serine phosphorylation of the receptor (18, 19) . We have reported that basal serine-phosphorylated D 1 receptor is increased in renal proximal tubules from genetically hypertensive rodents as well as from humans with essential hypertension (3, 16) .
The seven members of the GRK family are divided into three subfamilies: GRK1 and GRK7 belong to the rhodopsin kinase subfamily; GRK2 and GRK3 belong to the ␤-adrenergic receptor kinase subfamily; and GRK4, GRK5, and GRK6 belong to the GRK4 subfamily (24, 25) . GRK2 expression and activity are increased in lymphocytes from patients with essential hypertension (26) and genetically hypertensive rats (27) . However, the increase in GRK2 expression and activity in the spontaneously hypertensive rat followed the development of hypertension (27) . Moreover, we found no difference in the sequence of the coding region of GRK2 between hypertensive and normotensive human subjects (unpublished data). It is possible that the increase in GRK2 activity in lymphocytes of hypertensive patients (26, 27) is secondary to the high blood pressure, as has been suggested for the increase in GRK5 activity and expression in rodents with genetic and induced hypertension (28) . Moreover, the ubiqui-tous expression of GRK2 and GRK3 is at odds with the recognized preeminence of the kidney in the pathogenesis of both rodent and human essential hypertension (1, 2) . The limited expression of GRK4 (24, 25) and the fact that the GRK4 gene locus is linked to hypertension (29) make GRK4 an attractive candidate for a pathogenetic mechanism in human hypertension. Therefore, we sought to determine whether GRK4 is expressed in renal proximal tubules and whether genetic variants of GRK4 affect renal function and blood pressure.
Methods
Tissue Culture. Human kidneys were obtained as fresh surgical specimens from white patients who had unilateral nephrectomy because of renal carcinoma. The patient records of the subjects were reviewed and classified into those with either normal blood pressure (n ϭ 9) or essential hypertension (n ϭ 14). Subjects with systolic blood pressures less than 140 mm Hg and diastolic blood pressures less than 90 mm Hg were considered normotensive. Subjects with systolic blood pressures equal to or greater than 140 mm Hg and͞or diastolic blood pressures equal to or greater than 90 mm Hg and͞or on antihypertensive medications were considered hypertensive.
Cultures of renal proximal tubule cells from histologically verified normal sections (5 ϫ 10 5 cells per well in 24-well plastic plates coated with 0.075% Type I collagen) were incubated at 37°C in 95% air͞5% CO 2 and grown in a serum-free medium consisting of a 1:1 mixture of DMEM and Ham's F-12 medium supplemented with selenium (5 ng͞ml), insulin (5 g͞ml), transferrin (5 g͞ml), hydrocortisone (36 ng͞ml), triiodothyronine (4 pg͞ml), and epidermal growth factor (10 ng͞ml) (16) . When subconfluent (90-95%), the cells were subcultured (passages 6-8) for use in experimental protocols by using trypsin-EDTA (0.05%, 0.02%). The culture conditions are conducive for growth of human renal proximal tubules that retain characteristics of renal proximal tubule cells (16 Light Microscopic Immunohistochemistry. Immunohistochemistry of kidney tissues and cells in culture fixed in HISTOCHOICE (Amresco, Solon, OH) was performed as described (16) . Affinity-column purified polyclonal human D 1 receptor antibodies were raised against a synthetic peptide sequence GSGETQPFC (amino acids 299-307; ref. 16) . Two commercially available GRK4 isoform antibodies were used (Santa Cruz Biotechnolo- (31) . Of the four isoforms of GRK4 in humans, only GRK4␣ can phosphorylate rhodopsin (25) . Because the D 1 agonist did not stimulate GRK activity in cells from normotensive subjects, the effect of GRK ␣͞␤ antibody was not tested. Number of studies: n ϭ 5͞group except at 1 min and 5 min where n ϭ 4͞group. #, P Ͻ 0.05 vs. 0 time, t test; * , P Ͻ 0.05 vs. 0 time, ANOVA for repeated measures, Scheffé 's test; a, P Ͻ 0.05 HT vs. NT, t test. Data are mean Ϯ SE. gy); one GRK4 antibody recognized both the ␣ and ␤ isoforms, whereas another recognized both the ␥ and ␦ isoforms. The specificity of these antibodies has been previously reported (24) .
Determination of GRK Activity. GRK activity was measured according to Benovic (31) . Renal proximal tubular extracts were prepared by homogenization in ice-cold lysis buffer containing (in mM): 25 Tris⅐HCl (pH 7.5), 5 EDTA, 5 EGTA with leupeptin (10 g͞ml), aprotinin (20 g͞ml), and 1 PMSF. The crude homogenate was centrifuged at 30,000 ϫ g for 30 min. The pellet was solubilized by 200 mM NaCl on ice for 30 min and centrifuged at 30,000 ϫ g for 30 min. The supernatant was used for all GRK assays and immunoblotting. Twenty micrograms of protein extract was incubated with rhodopsin-enriched rod outer segments in assay buffer with 10 mM MgCl 2 and 0.1 mM ATP (containing [␥-32 P]ATP). After incubation in white light for 15 min at room temperature, the reaction was stopped with ice-cold lysis buffer and centrifuged at 13,000 ϫ g for 15 min. The pellet was resuspended in Laemmli buffer and subjected to 12% SDS͞PAGE. The gels were subjected to autoradiography, and the phosphorylated rhodopsin was quantified by using both densitometry and radioactive counting of the excised bands at the appropriate size. GRK activity was also measured in the presence or absence of a GRK4 ␥͞␦ antibody.
GRK4 Oligonucleotides. The effects of inhibition of GRK4 activity on cAMP accumulation and levels of immunoreactive GRK4 ␥͞␦ were determined by treating renal proximal tubule cells with vehicle, sense, scrambled, or antisense GRK4 propyne͞ phosphorothioate oligonucleotides (5 nM) for 4-16 h. The cells were then washed and reincubated for a total incubation time of 24 to 72 h. Two antisense oligonucleotides were used: 5Ј-CAC GAT GTT CTC GAG CTC CAT-3Ј, complementary to bases 255-275, and 5Ј-CTC CAT GTC CTG GCG CCG-3Ј, complementary to bases 243-260 (25) . Sense (5Ј-ATG GAG CTC GAG AAC ATC GTG-3Ј) or scrambled antisense (5Ј-ACC CTT GCG TCC GCT GCG-3Ј) oligonucleotides were used as controls. These sequences are common to all GRK4 isoforms. GRK4 and GRK6 have the same sequence in the first 18 bases but not in the 5Ј non-coding region (24, 25, 32) .
Immunoprecipitation. Proximal tubule cells were incubated with vehicle, fenoldopam, sense, scrambled, or antisense propyne͞ phosphorothioate GRK4 oligonucleotides (5 nM) as described above. The membranes were lysed with ice-cold lysis buffer (PBS͞1% Nonidet P-40͞0.5% sodium deoxycholate͞0.1% SDS͞1 mM EDTA͞1 mM EGTA͞1 mM sodium vanadate͞1 mM NaF͞1 mM PMSF͞10 g/ml aprotinin͞10 g/ml leupeptin). The lysates were incubated with IgG-purified anti D 1 receptor on ice for 1 h and protein-A agarose for 12 h with rocking at 4°C. The proteins separated by SDS͞PAGE were electrophoretically transferred onto nitrocellulose membranes. The transblot sheets were blocked with 5-10% nonfat dry milk in 10 mM Tris⅐HCl (pH 7.5), 150 mM NaCl, and 0.1% Tween-20 and were incubated with diluted affinity-purified polyclonal anti-phosphoserine antibody (Zymed; ref. 16 ). In some cases, the cells were labeled with 32 P and immunoprecipitated with anti-D 1 receptor antibody. The autoradiograms and immunoblots, visualized with the ECL system (Amersham Pharmacia), were quantified by densitometry (16) .
Transgenic Mice. Two constructs were used to generate transgenic mice. The full-length wild-type hGRK4␥ cDNA was obtained by PCR by using the GRK4␣ cDNA in pTRE plasmid as template. The A142V polymorphism was obtained by using site-directed mutagenesis. The two cDNAs were subcloned into pcDNA3.1. Expression of the cDNA insert was under the control of the cytomegalovirus promoter and bovine growth hormone (BGH) poly(A) signal. Full-length cDNA was verified by sequencing.
The mice were produced by microinjecting the cDNA constructs into fertilized eggs obtained from the mating of a (C57BL͞6J ϫ SJL͞J) F 1 female mouse and a (C57BL͞6J ϫ SJL͞J) F 1 male mouse at the University of Michigan Transgenic Animal Model Core. The presence of the transgene in the transgenic mice was verified by PCR. The first set of PCR primers (pcDNA, sense 5Ј-CGACTCACTATAGGGAGAC-3Ј; hGRK4, antisense 5Ј-ATGGTTCCCCTCTTAGGTAG-3Ј) generated a 530-bp fragment. The second set PCR primers (pcDNA, sense 5Ј-CGACTCACTATAGGGAGAC-3Ј; hGRK4, antisense 5Ј-CTTGATTCTTTGATCGACCTCCTCCC-3Ј) generated a 1,260-bp fragment. Twenty-two mice carrying wild-type hGRK4␥ and 10 mice carrying hGRK4␥ A142V were identified. Both wild-type and A142V hGRK4␥ were expressed in the kidney as determined by reverse transcription-PCR, immunoblotting, and immunohistochemistry.
Blood Pressure and Renal Functional Studies. The animal studies were approved by the Georgetown University Animal Care and Use Committee. The mice were anesthetized with pentobarbital (50 mg͞kg i.p.), placed on a heated board to maintain body temperature at 37°C, and tracheotomized (33) . Catheters were inserted into the femoral vessels for fluid administration, blood drawing, and blood pressure monitoring. Urine was collected via a suprapubic cystostomy. After a 60-min equilibration period, a baseline 30-min collection period was obtained. Thereafter, fenoldopam was infused intravenously at 2 g͞kg body weight͞ min for 30 min. Urine was collected during the drug infusion and Fig. 3 . Normalization of D1-like agonist-induced stimulation of cAMP accumulation in renal proximal tubule cells from hypertensive (HT) subjects by GRK4 antisense oligonucleotides. GRK4 antisense propyne͞phosphorothioate oligonucleotides normalized the ability of fenoldopam to stimulate cAMP accumulation in HT; a slight increase was noted in normotensives (NT). GRK4 sense or scrambled oligonucleotides did not significantly affect the ability of fenoldopam to stimulate cAMP accumulation in either NT or HT. Basal cAMP production was similar in hypertensive (940 Ϯ 34 fmol͞mg protein͞30 min, n ϭ 8) and normotensive subjects (1,015 Ϯ 36 fmol͞mg protein͞30 min, n ϭ 6; P ϭ 0.10, t test). GRK4␥͞␦ immmunoreactive levels (Inset) and GRK4␣͞␤ (not Results were similar by using two different oligonucleotides as described in Methods. Four of the eight hypertensive subjects were homozygous in at least one of the polymorphic sites (nucleotide positions 448 and 679, n ϭ 1; 679, n ϭ 1; and 1711, n ϭ 2). Uncoupling without GRK4 gene variants could be interpreted to indicate the presence of other meaningful GRK4 polymorphisms or there other causes of uncoupling besides GRK4 gene variants. Data are mean Ϯ SE. Number of experiments is in parentheses. Each n represents cells from one subject. a, P Ͻ 0.05 NT vs. HT, t test; * , P Ͻ 0.05 vs. other groups in HT, ANOVA for repeated measures, Scheffé 's test.
for another two 30-min periods, thereafter. Blood (50 l) was obtained from the femoral artery before the drug infusion and at the end of the last urine collection period. In some mice, bolus injections of fenoldopam (1, 10, 100, and 1000 ng) and the effect on blood pressure were monitored for 10 min, and the time for blood pressure to recover to preinjection levels. At the conclusion of the experiment, the mice were killed with an i.v. injection of pentobarbital (100 mg͞kg).
Statistical Analysis. The data are expressed as means Ϯ SE. Significant differences among and within groups were determined by ANOVA for n Ͼ 2 and t test for n ϭ 2. N refers to the number of treatment groups or experiments, cell lines, or mice as indicated.
Results and Discussion
GRK4 was previously thought to be expressed mainly in testes and the brain (24, 25) . However, GRK4␥ has been reported to be expressed in human myometrium (34) . We detected mRNA of all of the reported GRK4 isoforms in renal proximal tubules (not shown). There were no differences in the protein expression of the isoforms of GRK4 (␣͞␤, ␥͞␦) in kidneys or cultured renal proximal tubule cells between hypertensive and normotensive subjects (not shown). However, basal and D 1 agonist-stimulated GRK activities were elevated in renal proximal tubular cells from hypertensive subjects (Fig. 1) . The increased GRK activity in cells from hypertensive subjects was probably caused, in part, by GRK4␥͞␦ because the antibody that recognizes these two GRK4 isoforms blocked the stimulatory effect of the D 1 -like agonist, fenoldopam, on GRK activity.
An initial step in the desensitization process is the phosphorylation of the G protein-coupled receptor by GRK (18, 19) . In our studies, basal (ligand-independent) GRK activity and serine phosphorylation of the D 1 receptor in renal proximal tubule cells was higher in hypertensive subjects than in normotensive subjects ( Figs. 1 and 2 ). As expected, fenoldopam increased the phosphorylation of the D 1 receptor and cAMP accumulation in cells from normotensive subjects. In contrast, fenoldopam failed to increase further the phosphorylation of the D 1 receptor and minimally increased cAMP accumulation in cells from hypertensive subjects (Figs. 2 and 3 ). The increased GRK4 activity was related to the diminished responses of the D 1 receptor in hypertension because antisense GRK4 oligonucleotides completely blocked the serine phosphorylation of the D 1 receptor and restored the ability of fenoldopam to stimulate cAMP accumulation in cells from hypertensive subjects. In contrast, in cells from normotensive subjects, antisense GRK4 slightly increased the ability of fenoldopam to stimulate cAMP accumulation and also diminished the magnitude of phosphorylation of the D 1 receptor (Figs. 2 and 3) . Antisense GRK4 oligonucleotides did not affect basal or forskolin-stimulated cAMP production (data not shown). Compared with fenoldopam alone, neither sense nor scrambled GRK4 oligonucleotides affected cAMP accumulation or receptor serine phosphorylation in either group. The almost complete suppression of the phosphorylation of the D 1 receptor and normalization of the cAMP response by GRK4 antisense oligonucleotides in renal proximal tubules from hypertensive subjects suggest that the major GRK involved in the phosphorylation and desensitization of the D 1 receptor in hypertension is GRK4 rather than other GRKs that may be expressed in this nephron segment.
Several single nucleotide polymorphisms (SNPs) have been noted in the coding region of the GRK4 gene, but their clinical relevance has not been investigated (24) . However, the GRK4 locus is linked with essential hypertension (29) . Sequencing of GRK4 cDNAs from normotensive and hypertensive subjects confirmed the presence of SNPs (24): nucleotide 448, CGT to CTT (amino acid R65L) and the two reported variants, nucleotide 679, GCC to GTC (amino acid A142V), and nucleotide 1711, GCG to GTG (amino acid A486V).
The increased GRK activity in cells from hypertensive subjects was attenuated by antibodies to GRK4␥͞␦; therefore, we determined whether the variations in the GRK4␥ or GRK4␦ genes have any functional consequences. Because we did not find any effect of GRK4␦ on D 1 receptor function (unpublished observations), we concentrated our studies on GRK4␥. The ability of fenoldopam to stimulate cAMP accumulation in CHO cells (in the absence of GRK4␥ expression) was similar to that noted in HEK-293 cells, a cell with low endogenous GRK activity ( Fig.  4A; ref. 35 ). The expression of wild-type GRK4␥ slightly decreased the ability of the D 1 agonist to stimulate cAMP production (Fig. 4A) . However, the D 1 receptor-mediated cAMP production was markedly impaired by GRK4␥ SNPs (R65L, A142V, A486V, and combined R65L plus A486V). The effect of wild-type or GRK4␥ SNPs was not due to differences in the quantity of the expression of either the D 1 receptor or GRK4␥ (not shown). Wild-type GRK4␥ or its variants did not affect the ability of forskolin to stimulate cAMP accumulation (not shown), indicating specificity of the interaction of GRK4␥ with the D 1 receptor. The action of fenoldopam was selective for the D 1 receptor because the fenoldopam effect was blocked by the D 1 -like antagonist SCH23390 (not shown). Expression of GRK4␥ SNPs was also associated with increased basal phosphorylation of the D 1 receptor (Fig. 4B) . These studies suggest that the increased basal phosphorylation of the D 1 receptor by GRK4␥, may explain, in part, the decreased responsiveness of the D 1 receptor in hypertension. Of the GRK4 isoforms (␣, ␤, ␥, and ␦), only GRK4␣ and GRK4␦ have been reported to be involved in the regulation of G protein-coupled receptors (e.g., ␤-adrenergic, luteinizing hormone, metabotropic glutamate, and M2 muscarinic receptors; refs. 24 and 35-40) . GRK4␥ may preferentially regulate D 1 receptors because it has not been found to have much activity in regulating other G proteincoupled receptors (24) .
Of the three GRK4␥ SNPs, GRK4␥ A142V had the most drastic effect on D 1 receptor function in the expression studies. Therefore, we compared the consequences of the expression of GRK4␥ wild type and GRK4␥ A142V in transgenic mice. The important role that GRK4␥ SNPs play in the regulation of blood pressure was buttressed by the demonstration that transgenic mice expressing GRK4␥ A142V were hypertensive whereas those expressing the wild-type GRK4␥ were normotensive (Table 1) . Furthermore, the heart weights were greater in hypertensive GRK4␥ A142V than in normotensive wild-type GRK4␥ mice. The hypotensive effects of bolus i.v. administration of fenoldopam were comparable in wild-type and GRK4␥ A142V transgenes (Fig. 5A) . However, the i.v. infusion of fenoldopam increased urine flow and sodium excretion in GRK4␥ wild-type mice but not in the hypertensive GRK4␥ A142V transgenes (Fig. 5B) . These results are in agreement with previous studies showing that the desensitization of the D 1 receptor in genetic hypertension is renal specific (3, 7, 8, 16) . The renal vasodilatory effect of D 1 -like agonists may be preserved in genetic hypertension (3) . Thus, the ability of fenoldopam to decrease renal vascular resistance is maintained in the spontaneously hypertensive rat (SHR) (41) . Fenoldopam increases effective renal plasma flow to a greater extent in salt-sensitive hypertensive than in normotensive subjects (15) . The ability of dopamine to relax renal artery strips is also increased in stroke-prone SHRs (42) . However, fenoldopam has been reported to fail to vasodilate the kidney of some patients with essential hypertension (43) . The ability of fenoldopam to counteract the renal vasoconstrictor effect of exogenous angiotensin II and inhibit tubuloglomerular feedback is also impaired in the SHR (44, 45) . It is possible that differences in published reports may be related to differences in classes of hypertension being studied (salt-sensitive vs. saltresistant) or different experimental conditions (basal tone vs. basal, ANOVA on ranks, Dunnet's test; ϩ, P Ͻ 0.05 vs. basal, t test; #, P Ͻ 0.05 GRK4␥ A142V vs. WT (wild-type). Blood pressures were not affected by fenoldopam infusion except for transient decreases in GRK4␥ A142V to the same level as the wild-type transgenes during recovery 1 (not shown). Differences in blood pressure and renal responses to D 1-like agonist infusion cannot be explained by differences in GRK4␥ or D1 receptor expression (data not shown).
reactivity to vasoconstrictors; ref.
3). Nevertheless, the preservation of the extrarenal vasodilatory, and the ''distal'' renal tubular responses to D 1 -like agonists explains the ability of fenoldopam, a D 1 -like agonist, to decrease blood pressure and produce a natriuresis in hypertensive subjects (15, 46) . Genes regulating the renin angiotensin system have been implicated in the pathogenesis of essential hypertension (47, 48) . In a cohort of Ghanian hypertensive subjects, we found that there was a significant interaction of GRK4 SNPs (termed FJ) with the SNPs of angiotensin converting enzyme, AT 1 angiotensin receptor, and angiotensinogen (49) . In a white population, hypertensives (n ϭ 89) and normotensives (n ϭ 90) differed significantly in disease risk as a function of R65L͞A486V haplotypes (unpublished data). Similar effects were also found in a Japanese population (hypertensives, n ϭ 122, normotensives, n ϭ 54), where normal subjects were deficient in 65L͞486V alleles, and interactions among A142V, A486V, and angiotensin converting enzyme alleles significantly associated with disease phenotypes (unpublished data). These GRK4 SNPs impaired the function of D 1 receptors, whether endogenously (renal proximal tubule cells) or exogenously (CHO cells) expressed, and increased blood pressure and impaired the diuretic and natriuretic effects of D 1 -like agonist stimulation. The failure of the kidney to excrete excess sodium chloride is thought to be crucial in the development of hypertension (1, 2) . The desensitization of the D 1 receptor in renal proximal tubules in hypertension may lead to a decreased ability of the kidney to eliminate a sodium chloride load (3, 6, 13, 15) . Genes that regulate renal sodium transport are important in the regulation of blood pressure (50) .
In summary, we have found a ligand-independent increase in GRK activity and decrease in D 1 receptor function in renal proximal tubule cells in human essential hypertension because of activating SNPs of GRK4␥. These studies show a candidate gene, whose locus is linked to (29) , and whose SNPs are associated with, essential hypertension, which has been shown to have pathophysiologic consequences in renal proximal tubule and CHO cells, to impair renal sodium excretion, and to cause hypertension in transgenic mice. We describe here a transgenic mouse model in which the pathogenesis of hypertension appears to mimic that reported for human essential hypertension. This model may be useful in the study of new approaches to the treatment of hypertension.
